WO2010110914A3 - Mammalian genes involved in infection - Google Patents

Mammalian genes involved in infection Download PDF

Info

Publication number
WO2010110914A3
WO2010110914A3 PCT/US2010/000916 US2010000916W WO2010110914A3 WO 2010110914 A3 WO2010110914 A3 WO 2010110914A3 US 2010000916 W US2010000916 W US 2010000916W WO 2010110914 A3 WO2010110914 A3 WO 2010110914A3
Authority
WO
WIPO (PCT)
Prior art keywords
infection
genes involved
mammalian genes
involved
mammalian
Prior art date
Application number
PCT/US2010/000916
Other languages
French (fr)
Other versions
WO2010110914A2 (en
Inventor
Natalie Mcdonald
Original Assignee
Zirus, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zirus, Inc. filed Critical Zirus, Inc.
Publication of WO2010110914A2 publication Critical patent/WO2010110914A2/en
Publication of WO2010110914A3 publication Critical patent/WO2010110914A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to cellular proteins that are involved in infection or are otherwise associated with the life cycle of one or more pathogens.
PCT/US2010/000916 2009-03-27 2010-03-26 Mammalian genes involved in infection WO2010110914A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21117809P 2009-03-27 2009-03-27
US61/211,178 2009-03-27

Publications (2)

Publication Number Publication Date
WO2010110914A2 WO2010110914A2 (en) 2010-09-30
WO2010110914A3 true WO2010110914A3 (en) 2011-05-19

Family

ID=42781722

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/000916 WO2010110914A2 (en) 2009-03-27 2010-03-26 Mammalian genes involved in infection

Country Status (1)

Country Link
WO (1) WO2010110914A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3015986A1 (en) * 2013-12-30 2015-07-03 Lvmh Rech APTAMERS INHIBITING THE ENZYMATIC ACTIVITY OF MMP-9 PROTEIN
CN106413394B (en) * 2014-05-30 2020-02-11 再生元制药公司 Humanized dipeptidyl peptidase IV (DPP4) animals
BR112019012573A2 (en) 2016-12-20 2019-11-19 Lts Lohmann Therapie Systeme Ag transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
EP3338768B1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
KR20210005114A (en) 2018-04-20 2021-01-13 텍사스 테크 유니버시티 시스템 Self-attenuated prophylactic and therapeutic vaccines against pathogens
BR112020026099A2 (en) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag transdermal therapeutic system containing asenapine
WO2021262799A1 (en) * 2020-06-23 2021-12-30 Flagship Pioneering, Inc. Anti-viral compounds and methods of using same
CN113444785B (en) * 2021-06-28 2022-06-21 甘肃农业大学 SSc-miR-122-5p related to piglet C-type clostridium perfringens infectious diarrhea and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070087008A1 (en) * 2004-02-24 2007-04-19 The Government Of The United States Of America As Rab9a, rab11a, and modulators thereof related to infectious disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070087008A1 (en) * 2004-02-24 2007-04-19 The Government Of The United States Of America As Rab9a, rab11a, and modulators thereof related to infectious disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAMARGOS, R.S. E. ET AL.: "Protective role of ETA endothelin receptors during the acute phase of Trypanosoma cruzi infection in rats.", MICROBES AND INFECTION., vol. 6, no. 7, June 2004 (2004-06-01), pages 650 - 656 *
GRANDER, W. ET AL.: "Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C.", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION., vol. 36, September 2006 (2006-09-01), pages 67 - 70 *
MARCHANT, D. ET AL.: "Bosentan enhances viral load via endothelin-1 receptor type-A-mediated p38 mitogen-activated protein kinase activation while improving cardiac function during coxsackievirus-induced myocarditis.", CIRCULATION RESEARCH., vol. 104, February 2009 (2009-02-01), pages 813 - 821 *
ROFFE, E. ET AL.: "Endothelin-1 receptors play a minor role in the protection against acute Trypanosoma cruzi infection in mice.", BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH., vol. 40, no. 3, March 2007 (2007-03-01), pages 391 - 399 *
SITBON, 0. ET AL.: "Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE., vol. 170, August 2004 (2004-08-01), pages 1212 - 1217 *

Also Published As

Publication number Publication date
WO2010110914A2 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
WO2011008956A3 (en) Mammalian genes involved in infection
WO2011146527A3 (en) Mammalian genes involved in infection
WO2010110914A3 (en) Mammalian genes involved in infection
WO2010134939A3 (en) Mammalian genes involved in infection
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
MY160552A (en) Low protein infant formula with increased essential amino acids
WO2010039778A3 (en) Mammalian genes involved in infection
IL222961A0 (en) Novel dna-dinding proteins and uses thereof
EP2408795A4 (en) Protein production in microorganisms of the phylum labyrinthulomycota
SG11201503308XA (en) PRODUCTION OF RECOMBINANT VACCINE IN <i>E. COLI</i> BY ENZYMATIC CONJUGATION
HK1215954A1 (en) Btnl9 proteins, nucleic acids, and antibodies and uses thereof btnl9
ZA201203603B (en) Lyophilization methods, compositions, and kits
MY161868A (en) Anti-bv8 antibodies and uses thereof
HK1168122A1 (en) Novel fluorescent dyes and uses thereof
ZA201102495B (en) Sulfonylurea-responsive repressor proteins
HUP1000366D0 (en) Novel proteins, their production process and use tereof
HK1142928A1 (en) Nucleic acid amplification in the presence of modified randomers
IL211929A0 (en) Ngf aptamer, compositions comprising the same and uses thereof
IL240134A0 (en) Novel proteins
AU329923S (en) Twin motor compressor
WO2012045067A3 (en) Mammalian genes involved in infection
WO2010144908A3 (en) Mammalian genes involved in tularemia and other infections
BR112013032223A2 (en) isolated nucleic acid molecule and composition
EP2639302A4 (en) Modified fluorescent protein
BRPI1009881A2 (en) adhesive composition with improved green strength

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10756503

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10756503

Country of ref document: EP

Kind code of ref document: A2